期刊文献+

分子动力学模拟三氯生对烯脂酰-ACP还原酶作用机制研究

Molecular dynamics simulation studies on the mechanism of triclosan binding with FabI
下载PDF
导出
摘要 本文利用分子动力学模拟分别研究了蛋白sa Fab I体系、sa Fab I-NADP+体系和sa Fab I-NADP+-TCL体系的稳定性、各氨基酸残基随模拟时间的波动情况以及活性位点处关键氨基酸残基构象的变化规律.研究表明,辅酶NADP+及抑制剂三氯生均可在不同程度上促使蛋白构象稳定.辅酶NADP+可以促使活性位点Loop区残基Y147-Y157残基构象变为规则的卷曲构象;抑制剂三氯生可以促使蛋白与底物结合位点Loop I区残基I94-E108和Loop II区残基R194-F204及活性位点Loop区残基Y147-Y157残基构象变为规则的卷曲构象,构象趋于稳定.上述研究发现对认识三氯生作为抗菌药物机制及相关药物设计具有重要指导意义. The impact of stability of all complexex, the volatility of each amino acid residues and the comformation of the active site loop of SaFabI, saFabI-NADP~ binary system and saFabI-NADP+-TCL ternary complex with simulation time were studied by molecular dynamics simulation. The study showed that the NADP+ and the inhibitor three could promote the stability of conformation of the protein in different degrees. The NADP+ could promote the stability of conformation of the active site loop Y147 Y157. And the NADP+ and TCL could promote the stability of the substrate-binding loopI I94 El08 and loopII R194- F204 and the active site loop Y147-Y157. These results aid our understanding of potent inhibitory activity of triclosan and related compounds.
出处 《天津理工大学学报》 2016年第4期43-47,共5页 Journal of Tianjin University of Technology
基金 国家自然科学基金(21176194 21476174)
关键词 烯脂酰ACP还原酶 三氯生 分子动力学模拟 作用机制 enoyl-ACP reductase triclosan molecular dynamics simulation mechanism
  • 相关文献

参考文献12

  • 1Pantosti A, Venditti M. What is MRSA [J ]. European Res- piratory Journal, 2009,34 : ! 190-1196.
  • 2Hidron A I, Edwards J R, Patel J, et al. Antimicrobial-resis- tam pathogens associated with healflware-associated infec- lions: annual smnmal of data reported to the National Heahhcare Safety Network at the Centers for Disease Con- trol and Prevention, 2006-2007 [J ]. Infection Control, 2008, 29:996-1011.
  • 3Fischbach M A,Walsh C T. Antibiotics for emerging pa- thogens [ J ]. Scienee, 2009,325 : 1089-1093.
  • 4Campbell J W,Cronan Jr J E. Bacterial fatty acid biosyn- ttlesis : targets for antibacterial drug discovery [J ]. AnnualReviews in Microbiology, 2001,55 : 305-332.
  • 5Payne D J,Warren P V, Hohnes D J, el al. Bacterial fatty- acid biosynthesis : a genomics- driven larget for antibacterial drug discovery [J]. Drug Discovery Today ,2001 (6) :537- 544.
  • 6Rosner J L. Susceptibilities of oxyR regulon mutants of Es- cherichia coli and Salmonella typhimurium to isoniazid [J].Antimicrobial Agents and Chemotherapy, 1993,37:2251- 2253.
  • 7Miyakawa S, Suzuki K, Noto T, et al. Thiolactumycin, a new antibiotic. IV. Biological properties and chemotherapeutic~ activity in mice [J ]. Tile Journal of Antibiotics , 1982,35 : 411-419.
  • 8Kumar K R,Rohini P,Md A R,et al. A review on occur- rence,fate and toxicity of triclosan [J]. World Journal of Pharmacy and Pharmaceutical Sciences,2015 (4) : 336 - 369.
  • 9Schiebel J,Chang A,Lu H,et al. Staphylococcus aureus FabI :inhibition,substrate recognition, and potential impli- cations fbr in vivo essentiality [ J ]. Structtn, 2012,20 : 802- 813.
  • 10Van Der Spoel D,Lindahl E,Hess B,et al. GROMACS: fast,flexible,and free [J]. Journal of Computational Chem- istt3, 2005,26: 1701-1718.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部